Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled RV6153 in Healthy Subjects and Asthma
NCT02517359Phase 1Terminated
- Sponsor
- RespiVert
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RV6153 in asthma and chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by RespiVert. Primary endpoints: Incidence of treatment emergent adverse events, Safety and tolerability assessed by ECG and 6 more. Started Jul 2015; status: terminated.
02
Drugs
RV6153
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02517359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02517359.